Natacha Mpile
Gerontology · Alpharetta, GANPI 1538671532
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 84 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $612, 2.3 times the $268 reported in 2022.
Across 84 payments — averaging $21.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$258
- Fresenius USA Marketing, Inc.$204
- Bayer$203
- Vifor Pharma, Inc.$182
- Lilly USA, LLC$124
- Amgen$115
- plus $696 from 18 others
What the payments were for
- Food & beverage$1,75799%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 13 | $258 |
| Fresenius USA Marketing, Inc. | 10 | $204 |
| Bayer | 10 | $203 |
| Vifor Pharma, Inc. | 9 | $182 |
| Lilly USA, LLC | 6 | $124 |
| Amgen(2 entities) | 6 | $115 |
| Otsuka America Pharmaceutical, Inc. | 4 | $95 |
| Daiichi Sankyo Inc. | 3 | $65 |
| Travere Therapeutics, Inc. | 2 | $57 |
| Astellas Pharma US Inc | 2 | $55 |
| Johnson & Johnson | 2 | $51 |
| Calliditas Therapeutics US Inc. | 2 | $48 |
| Aurinia Pharma U.S., Inc. | 2 | $38 |
| AbbVie | 2 | $37 |
| Boston Scientific | 1 | $36 |
| Pfizer | 2 | $33 |
| Ardelyx, Inc. | 1 | $27 |
| OPKO Pharmaceuticals, LLC | 1 | $25 |
| Dexcom, Inc. | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Corcept Therapeutics | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Novo Nordisk | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
How this compares
$1,781 in reported general payments places this provider in the 70th percentile of 197 gerontology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 11 | $12,204 |
| VeltassaPatiromer Calcium Sorbitex | 16 | $12,202 |
| Sevelamer Carbonate | 26 | $10,003 |
| FarxigaDapagliflozin Propanediol | 11 | $8,480 |
| Midodrine Hcl | 34 | $2,103 |
| Calcium Acetate | 12 | $1,070 |
| Potassium Chloride | 33 | $809 |
| Bumetanide | 15 | $784 |
| Torsemide | 52 | $701 |
| Calcitriol | 83 | $690 |
| Sodium Polystyrene Sulfonate | 13 | $670 |
| Nifedipine ErNifedipine | 22 | $357 |
| Hydralazine Hcl | 59 | $296 |
| Carvedilol | 52 | $258 |
| Amlodipine Besylate | 62 | $255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $204 | $12,20411 claims |
| AstraZenecaFarxiga | $258 | $8,48011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 197 gerontology providers in Georgia.
Other gerontology in Alpharetta
- Carolyn ClevengerAtlanta$65K
- Mitzi LewisAtlanta$37K
- Constance MeinkenAtlanta$36K
- Britni JohnsonSavannah$24K
- Doreen AbrigoWarner Robins$14K
- Taylor SwineaWaycross$10K
- Michelle DudleyMacon$10K
- Kathleen BradfordAtlanta$8K
- Teresa VickersWarner Robins$6K
- Melissa RusterucciPeachtree City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.